In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

30 mg twice per day, deucravacitinib (Sotyktu, Bristol Myers Squibb) 6 mg or 12 mg once per day, tofacitinib (Xeljanz, Pfizer) 5 mg twice per day and upadacitinib (Rinvoq, Abbvie) 15 mg daily.

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq ... to receive a 7.5 mg or 15 mg dose of ...

The positive opinion is based on results from the pivotal Phase 3 SELECT-GCA trial that evaluated the efficacy and safety of upadacitinib in adults with giant cell arteritis (GCA)1The primary ...

1 In the first study period, patients were randomized to receive upadacitinib 7.5 mg or 15 mg in combination ... today and in the future." RINVOQ is approved in the European Union (EU) for the ...